Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
First Claim
1. A method of treating a human or animal host with the intent of reducing tissue damage occurring at an inflammatory site in any part of the body of the host experiencing a phagocyte-mediated inflammatory condition, said method comprising:
- administering in vivo a monoclonal antibody having the binding specificity of the MY904 murine monoclonal antibody produced by the cell line A.T.C.C. No. HB 9510 which will bind specifically to an epitope expressed on the CD11b part of the CD11/CD18 glycoprotein of the Mol antigen expressed on the surface of granulocytes and other phagocytic cells and will inhibit the CD11/CD18 adhesion dependent cellular interactions of such cells reflecting their immunological inflammatory response function which contributes to such damage and yet, not interfere with the binding of iC3b.
2 Assignments
0 Petitions
Accused Products
Abstract
A method of reducing tissue injury in humans or other animal species using a monoclonal antibody to inhibit specific phagocyte functions. The monoclonal antibody is selected to bind to phagocytic leukocytes for the purpose of inhibiting migration to an inflammatory site in the body and to inhibit the adhesion and spreading of activated leukocytes reaching such an area and then, block release of toxic substances by these cells. The monoclonal antibody is administered in vivo prior or early in the course of an experience leading to an injurious inflammatory response such as can result from restoration of myocardial blood flow interrupted by an acute coronary thrombosis.
78 Citations
11 Claims
-
1. A method of treating a human or animal host with the intent of reducing tissue damage occurring at an inflammatory site in any part of the body of the host experiencing a phagocyte-mediated inflammatory condition, said method comprising:
administering in vivo a monoclonal antibody having the binding specificity of the MY904 murine monoclonal antibody produced by the cell line A.T.C.C. No. HB 9510 which will bind specifically to an epitope expressed on the CD11b part of the CD11/CD18 glycoprotein of the Mol antigen expressed on the surface of granulocytes and other phagocytic cells and will inhibit the CD11/CD18 adhesion dependent cellular interactions of such cells reflecting their immunological inflammatory response function which contributes to such damage and yet, not interfere with the binding of iC3b. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 11)
-
9. A method of treating a human host with the intent of reducing tissue damage occurring at an inflammatory site in the body of the human experiencing an inflammatory condition, said method comprising:
infusing into the body prior to or during said inflammatory condition a quantity of murine monoclonal antibody having the binding specificity of the MY904 monoclonal antibody developed from the hybridoma cell line A.T.C.C. No. HB 9510 which will bind specifically to an epitope expressed on the CD11b, 155,000 dalton molecular weight peptide of the Mol antigen expressed on the surface of neutrophils and will inhibit the CD11/CD18 adhesion dependent intercellular reactions of neutrophils reflecting their immunological response function which contributes to such damage and yet, not interfere with binding of iC3b.
-
10. A method of reducing myocardial inflammation damage in a human patient experiencing an acute coronary thrombosis, said patient having been treated initially either medically or surgically to renew myocardial blood flow at the inflammatory site, said method comprising supplying intravenously at least prior to such blood flow renewal a quantity of a murine monoclonal antibody which binds specifically an epitope expressed on CD11b part of the CD11/CD18 glycoprotein of the Mol surface antigen of neutrophils whereby to inhibit the adhesive-dependent cellular interactions of the neutrophils at said site reflecting their immunological response function whereby to decrease the deleterious action of neutrophils at said site and without interfering in the binding of iC3b to the antibody bound target neutrophils.
Specification